8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements
AbbVie filed an 8‑K on Jan 7, 2026.
Filed with the SEC on · Summarized by InvestorsBot
AbbVie filed an 8‑K on Jan 7, 2026. Exhibit 99.1 contains updated company guidance that includes the impact of acquired IPR&D and milestone expense—investors should review the exhibit for any changes to FY outlook. $ABBV 📄 #AbbVie #guidance #pharma
Exhibit 104 (Inline XBRL) included the cover page; the report was signed by CFO Scott T. Reents on Jan 7, 2026. Administrative filing — see Exhibits 99.1/104 for detail. $ABBV ⚖️ #AbbVie #SECfiling
Key takeaway: guidance now explicitly reflects acquired IPR&D and milestone costs — potential near‑term FY impact depending on exhibit details. Read Exhibit 99.1 for amounts/timing. $ABBV 📊 #AbbVie #earnings